William Blair
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.
William Blair Initiates Coverage of 10x Genomics With Outperform Rating
Analysts for the investment bank, which co-managed a recent 10x stock offering, said the company could "redefine the way biological analysis is performed."
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
10x Genomics Prices Upsized $440M Public Offering
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
10x Genomics to Sell 3.5M Shares in Public Offering
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
Jul 26, 2018
Veracyte Prices $51.3M Public Offering
Jan 5, 2018
Jan 20, 2015
Investment Banks Upgrade Fluidigm, Hologic
Jun 23, 2014
William Blair Upgrades Sequenom to Outperform
May 29, 2012